We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific Bets on Growth Through Strategic M&A Deals
Read MoreHide Full Article
Key Takeaways
Boston Scientific acquired Valencia Technologies to expand into bladder dysfunction treatment.
BSX added Nalu Medical's nerve stimulation platform to strengthen its Pain franchise.
Boston Scientific agreed to acquire Penumbra to enter fast-growing vascular segments.
Boston Scientific (BSX - Free Report) continues to prioritize strategic tuck-in M&A as its primary capital allocation focus, supporting entry into adjacencies, expanding technology platforms and enhancing long-term competitive positioning.
In April 2026, Boston Scientific completed the acquisition of Valencia Technologies Corporation, strengthening its Urology portfolio with innovative solutions for bladder dysfunction. Valencia Technologies’ eCoin System is an implantable tibial nerve stimulation (ITNS) device for the treatment of urge urinary incontinence. The addition of the eCoin system to the Boston Scientific portfolio will enable the company to expand into ITNS, a high-growth adjacent market for its Urology business.
Boston Scientific also closed the acquisition of Nalu Medical, adding a differentiated peripheral nerve stimulation (PNS) platform to its Pain franchise within Neuromodulation.
In January 2026, Boston Scientific entered into a definitive agreement to acquire Penumbra in a cash-and-stock transaction valuing the latter at $374 per share. Penumbra develops advanced medical devices for vascular and neurovascular procedures, such as Lightning Bolt and Lightning Flash computer-assisted vacuum thrombectomy (CAVT) systems. This acquisition offers Boston Scientific an opportunity to enter new, fast-growing segments within the vascular space. The transaction is expected to be completed in 2026, subject to receipt of Penumbra's stockholder approval and the satisfaction of other customary closing conditions.
Peer Update
In March 2026, Abbott Laboratories (ABT - Free Report) completed the acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people. Following the completion of the acquisition, Exact Sciences became a wholly owned subsidiary of Abbott.
Post-acquisition, Abbott now offers a comprehensive suite of products, including the Cologuard test, a market-leading noninvasive colorectal cancer screening option; Oncotype DX, which informs personalized treatment decisions for patients with early-stage breast cancer; Oncodetect, a tumor-informed molecular residual disease (MRD) test designed to help identify cancer recurrence and guide follow-up care; and Cancerguard, a multi-cancer early detection blood test.
Medtronic plc (MDT - Free Report) continues to prioritize high-growth merger and acquisition opportunities to complement its core businesses and deliver sustained value for its physician and hospital partners.
In April 2026, Medtronic completed the acquisition of CathWorks, a privately held medical device company, to strengthen its interventional cardiology portfolio. The acquisition follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio System. The acquisition is valued at $585 million with potential undisclosed earn-out payments post-acquisition.
BSX Stock Price Performance
Shares of Boston Scientific have lost 50.6% over the past year compared with the industry’s decline of 33.1%. The S&P 500 composite has grown 29% in the same period.
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-sales ratio (P/S) of 3.50X, above the industry median of 3.03X.
Image Source: Zacks Investment Research
BSX Stock Consensus Estimate Trend
The Zacks Consensus Estimate for BSX’s 2026 earnings has moved south 2% over the past 30 days.
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific Bets on Growth Through Strategic M&A Deals
Key Takeaways
Boston Scientific (BSX - Free Report) continues to prioritize strategic tuck-in M&A as its primary capital allocation focus, supporting entry into adjacencies, expanding technology platforms and enhancing long-term competitive positioning.
In April 2026, Boston Scientific completed the acquisition of Valencia Technologies Corporation, strengthening its Urology portfolio with innovative solutions for bladder dysfunction. Valencia Technologies’ eCoin System is an implantable tibial nerve stimulation (ITNS) device for the treatment of urge urinary incontinence. The addition of the eCoin system to the Boston Scientific portfolio will enable the company to expand into ITNS, a high-growth adjacent market for its Urology business.
Boston Scientific also closed the acquisition of Nalu Medical, adding a differentiated peripheral nerve stimulation (PNS) platform to its Pain franchise within Neuromodulation.
In January 2026, Boston Scientific entered into a definitive agreement to acquire Penumbra in a cash-and-stock transaction valuing the latter at $374 per share. Penumbra develops advanced medical devices for vascular and neurovascular procedures, such as Lightning Bolt and Lightning Flash computer-assisted vacuum thrombectomy (CAVT) systems. This acquisition offers Boston Scientific an opportunity to enter new, fast-growing segments within the vascular space. The transaction is expected to be completed in 2026, subject to receipt of Penumbra's stockholder approval and the satisfaction of other customary closing conditions.
Peer Update
In March 2026, Abbott Laboratories (ABT - Free Report) completed the acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people. Following the completion of the acquisition, Exact Sciences became a wholly owned subsidiary of Abbott.
Post-acquisition, Abbott now offers a comprehensive suite of products, including the Cologuard test, a market-leading noninvasive colorectal cancer screening option; Oncotype DX, which informs personalized treatment decisions for patients with early-stage breast cancer; Oncodetect, a tumor-informed molecular residual disease (MRD) test designed to help identify cancer recurrence and guide follow-up care; and Cancerguard, a multi-cancer early detection blood test.
Medtronic plc (MDT - Free Report) continues to prioritize high-growth merger and acquisition opportunities to complement its core businesses and deliver sustained value for its physician and hospital partners.
In April 2026, Medtronic completed the acquisition of CathWorks, a privately held medical device company, to strengthen its interventional cardiology portfolio. The acquisition follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio System. The acquisition is valued at $585 million with potential undisclosed earn-out payments post-acquisition.
BSX Stock Price Performance
Shares of Boston Scientific have lost 50.6% over the past year compared with the industry’s decline of 33.1%. The S&P 500 composite has grown 29% in the same period.
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-sales ratio (P/S) of 3.50X, above the industry median of 3.03X.
Image Source: Zacks Investment Research
BSX Stock Consensus Estimate Trend
The Zacks Consensus Estimate for BSX’s 2026 earnings has moved south 2% over the past 30 days.
Image Source: Zacks Investment Research
BSX stock currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.